We are extremely pleased and enthusiastic that we can count upon the valued support of Business Angels Marne-Ardennes (BAMA, former Reims Business Angels)!
This enables Apmonia Therapeutics to accelerate the development of its lead candidate AP-01 in solid tumors, while strengthening R&D team and increasing the company’s attractiveness towards industrial partners and investors.
We feel very honored to be recipient of the i-Lab 2020 award. Support given to our ambitious project by Ministère de l’Enseignement Supérieur et de la Recherche (France) and Bpifrance will help developing Apmonia Therapeutics‘ innovative technology for the treatment of orphan oncology diseases.
We are thrilled to announce that Institut national du cancer (INCa) will provide financial support to a unique industry-academic R&D partnership gathering together Apmonia Therapeutics, MEDyC unit (CNRS UMR7369, Université de Reims Champagne-Ardenne, Prof. Stephane Dedieu, PI) and Gustave Roussy Cancer Center (INSERM U981, Dr. Alexandra Leary).
As part of the “Cancer Biology and Basic Sciences” 2020 call for proposals, our ambitious project aims at opening new therapeutic perspectives for the treatment of ovarian cancer, one of the highest unmet medical needs in oncology.
more :
https://www.e-cancer.fr/Institut-national-du-cancer/Appels-a-projets/Appels-a-projets-resultats/PLBIO-2020
Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week.
We are grateful to Jean-Yves HEYER as well as everyone in the INVEST IN REIMS team. It was a great evening!
Press release: SATT Nord and Apmonia Therapeutics have entered into agreements in which Apmonia Therapeutics has been granted an exclusive worldwide license for the development and commercialization of the innovative anti-cancer immunotherapy (TAX2 peptide).
#immunotherapy #fightcancer #peptide
more :
